Matrix Gla Protein (MGP), a New Drug Target to Modulate Uterine Quiescence and Contractility
- 詳細技術說明
- None
- *Abstract
-
Pretermbirth is a significant public health problem worldwide. In the US alone,~500,000 premature infants are born annually, yet the underlying mechanisms areunclear. Currently, there is no intervention that effectively protects againstpreterm birth or predicts risk for preterm birth. Researchers at NationwideChildren’s Hospital discovered that Matrix Gla Protein (MGP) is associated withuterine quiescence. This novel discoveryrepresents a promising new drug target for preventing or ceasing preterm laborin at-risk mothers.
- *Inquiry
- Andrew CorrisThe Research Institute at Nationwide Children’s HospitalOffice of Technology Commercialization700 Children’s DriveColumbus, OH 43205T: (614) 355-1604 F: (614) 722-2716Andrew.Corris@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- 國家
- Not Available
- 申請號碼
- None
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
